Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | LPL | P06858 | 3/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28131136 | 0.94 | TAAR1 (0.53) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL2998787 | 0.94 | CYP1A2 (0.60) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL19304390 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL9802185 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL2442972 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL28656641 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL1577575 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| SCHEMBL5599017 | 0.92 | CYP1A2 (0.61) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| Propionaldehyde SCHEMBL28761999 | 0.89 | CYP1A2 (0.53) | TAAR1CYP1A2CYP2D6CYP2C19LPL | |
| Nitrogen SCHEMBL23668052 | 0.89 | CYP1A2 (0.58) | TAAR1CYP1A2CYP2D6CYP2C19LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3936192-B1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| CN-110799490-B | 3-arylpropionamide compound and method for producing 3-arylpropionate compound | 住友化学株式会社 | 2023-05-02 | — | — | CN | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| EP-3936192-A1 | PYRROLOPYRAZOLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| CN-1538848-A | Novel Benzo-fused heterocycles | ������˹ҩƷ��˾ | 2004-10-20 | — | — | CN | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-3992536-A | SEDATIVES AND MUSCLE RELAXANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3931185-A | SEDATIVES, MUSCLE RELAXANT | BOEHRINGER INGELHEIM GMBH (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | TAAR1 277/4885CYP1A2 600/4885CYP2D6 886/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | TAAR1 4460/4885CYP1A2 23/4885CYP2D6 9/4885 |
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HPD, TALDO1, OGG1 | TAAR1 3413/4885CYP1A2 537/4885CYP2D6 315/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | TAAR1 3518/4885CYP1A2 3284/4885CYP2D6 4245/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | TAAR1 4602/4885CYP1A2 2179/4885CYP2D6 2394/4885 |
| US-12240855-B2 | Pyrrolopyrazole derivative | PTDSS1, PTDSS2, SMPD1 | TAAR1 4602/4885CYP1A2 2179/4885CYP2D6 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.